TrovaGene, Inc. (TROV): Price and Financial Metrics
TROV Price/Volume Stats
| Current price | $1.19 | 52-week high | $3.46 |
| Prev. close | $1.20 | 52-week low | $0.70 |
| Day low | $1.16 | Volume | 166,400 |
| Day high | $1.19 | Avg. volume | 648,892 |
| 50-day MA | $1.05 | Dividend yield | N/A |
| 200-day MA | $1.47 | Market Cap | 13.10M |
TROV Stock Price Chart Interactive Chart >
TrovaGene, Inc. (TROV) Company Bio
Trovagene, Inc. focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. The company was founded in 1999 and is based in San Diego, California.
Latest TROV News From Around the Web
Below are the latest news stories about Trovagene Inc that investors may wish to consider to help them evaluate TROV as an investment opportunity.
Trovagene Announces First Quarter 2020 Results and HighlightsTrovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today announced company highlights and financial results for the first quarter ended March 31, 2020. The company is issuing this press release in lieu of conducting a conference call. |
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive OfficerSAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant… |
Trovagene Announces Fourth Quarter and Full-Year 2019 ResultsSAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today… |
Trovagene Receives Approximately $1.45 Million From Exercise of WarrantsSAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,… |
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASHSAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today… |
TROV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -75.51% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -60.63% |
| 2018 | -85.80% |
Continue Researching TROV
Here are a few links from around the web to help you further your research on Trovagene Inc's stock as an investment opportunity:Trovagene Inc (TROV) Stock Price | Nasdaq
Trovagene Inc (TROV) Stock Quote, History and News - Yahoo Finance
Trovagene Inc (TROV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...